Globalpharma expands across manufacturing stack + Dutch TMF Group secures DIFC license

Globalpharma widens its pharma stack

Dubai Investments’ pharma arm is building its manufacturing firepower with seven MoUs spanning R&D, automation, financing, localization, and sustainability as it looks to strengthen capabilities across the UAE pharma value chain, according to a statement (pdf).

Who’s involved: India’s ZIM Laboratories and Molkem Chemicals will support product development and localization, while US-based industrial automation firm Rockwell Automation, Masibus — part of France’s Sonepar Group — and UAE-based 386 Sky Solar will support automation, manufacturing efficiency, and a rooftop solar plant at its Dubai Investments Park facility.

Emirati players are also central to the push: Emirates Development Bank will support structured financing and expansion, while Mubadala Bio’s Al Ittihad Drug Store and the Emirates Drug Establishment will help strengthen distribution, regulatory alignment, and meds security initiatives.

ICYMI- Globalpharma is also building beyond the UAE, with its Angola manufacturing facilityexpected to begin production in 2027, as it looks to scale Emirati-made pharma deeper into export markets.

TMF Group secures DIFC license

Dutch fund administrator and corporate service provider TMF Group has secured regulatory approval to operate in Dubai International Financial Center (DIFC), according to a press release. The firm secured approval as a fund administrator and as a corporate service provider.

TMF Group? The firm already operates across 87 jurisdictions globally and works with large multinational corporations, financial institutions, and private capital players.